233 related articles for article (PubMed ID: 29784748)
21. Emerging biological therapies to treat acute lymphoblastic leukemia.
Huguet F; Tavitian S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):107-121. PubMed ID: 27820973
[TBL] [Abstract][Full Text] [Related]
22. Cytokine release syndrome and complete remission of extra medullary acute lymphoblastic leukemia of the breast with CAR-T and radiation therapy.
Ragoonanan D; Tambaro FP; Khazal SJ; Tewari P; Petropoulos D; Champlin R; Mahadeo KM
Pediatr Blood Cancer; 2021 May; 68(5):e28839. PubMed ID: 33258192
[No Abstract] [Full Text] [Related]
23. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
[TBL] [Abstract][Full Text] [Related]
24. How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
Wieduwilt MJ
Best Pract Res Clin Haematol; 2017 Sep; 30(3):201-211. PubMed ID: 29050693
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with the clinical outcome of patients with relapsed/refractory CD19
Ortiz-Maldonado V; Rives S; Español-Rego M; Alonso-Saladrigues A; Montoro M; Magnano L; Giné E; Pascal M; Díaz-Beyá M; Castella M; Català A; Faura A; Rodríguez-Lobato LG; Oliver-Caldes A; Martínez-Roca A; Rovira M; González-Navarro EA; Ortega JR; Cid J; Lozano M; Garcia-Rey E; Fernández S; Castro P; Jordan I; Villamor N; Aymerich M; Torrebadell M; Deyà À; Fernández de Larrea C; Benitez-Ribas D; Trias E; Varea S; Calvo G; Esteve J; Urbano-Ispizua A; Juan M; Delgado J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907029
[No Abstract] [Full Text] [Related]
26. The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies.
Fedorov VD; Upadhyay VA; Fathi AT
Curr Hematol Malig Rep; 2016 Jun; 11(3):165-74. PubMed ID: 26939921
[TBL] [Abstract][Full Text] [Related]
27. Immune and Cell Therapy in Non-Hodgkin Lymphoma.
Merryman RW; Houot R; Armand P; Jacobson C
Cancer J; 2020; 26(3):269-277. PubMed ID: 32496460
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia.
Wyatt KD; Bram RJ
Hum Immunol; 2019 Jun; 80(6):400-408. PubMed ID: 30716352
[TBL] [Abstract][Full Text] [Related]
29. [Not Available].
Feuchtinger T
Drug Res (Stuttg); 2018 Nov; 68(S 01):S12-S13. PubMed ID: 30453365
[No Abstract] [Full Text] [Related]
30. CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report.
Wen S; Niu Z; Xing L; Wang Y; Li H; Kuang N; Luo J; Zhang X; Wang F
BMC Cancer; 2018 Nov; 18(1):1143. PubMed ID: 30458755
[TBL] [Abstract][Full Text] [Related]
31. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
32. [Not Available].
Dourthe MÉ; Yakouben K; Chaillou D; Lesprit E; Dalle JH; Baruchel A
Bull Cancer; 2018 Dec; 105 Suppl 2():S147-S157. PubMed ID: 30686353
[TBL] [Abstract][Full Text] [Related]
33. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
34. The what, when and how of CAR T cell therapy for ALL.
Frey N
Best Pract Res Clin Haematol; 2017 Sep; 30(3):275-281. PubMed ID: 29050700
[TBL] [Abstract][Full Text] [Related]
35. Novel therapy for childhood acute lymphoblastic leukemia.
Santiago R; Vairy S; Sinnett D; Krajinovic M; Bittencourt H
Expert Opin Pharmacother; 2017 Aug; 18(11):1081-1099. PubMed ID: 28608730
[TBL] [Abstract][Full Text] [Related]
36. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
Leoni V; Biondi A
Haematologica; 2015 Mar; 100(3):295-9. PubMed ID: 25740105
[No Abstract] [Full Text] [Related]
37. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
Su CT; Ye JC
J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
[TBL] [Abstract][Full Text] [Related]
38. Pediatric Acute Lymphoblastic Leukemia.
Rheingold SR
Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469898
[No Abstract] [Full Text] [Related]
39. Should immunologic strategies be incorporated into frontline ALL therapy?
Rank CU; Stock W
Best Pract Res Clin Haematol; 2018 Dec; 31(4):367-372. PubMed ID: 30466749
[TBL] [Abstract][Full Text] [Related]
40. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
